MRKR MARKER THERAPEUTICS INC Contract Awards 8-K Filing 2024 - NIH Grant Award Marker Therapeutics, Inc. announced a $2 million grant from the NIH to support clinical trials of MT-601 for non-Hodgkin's lymphoma patients who have relapsed after CAR T cell therapy.Get access to all SEC 8-K filings of the MARKER THERAPEUTICS INC